Edward Man-Lik Choi

Assistant Professor

London School of Hygiene & Tropical Medicine

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom Professors in Immunology Immunology professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Edward Man-Lik Choi is an Assistant Professor at the London School of Hygiene and Tropical Medicine in the UK. His research focuses on vaccine safety and efficacy, with recent work including clinical trials on Ebola virus vaccines, particularly in vulnerable populations such as pregnant women and HIV-positive individuals. He is also involved in studies related to COVID-19 vaccines and the transmission of SARS-CoV-2.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2020

Collaborators (4)

Chrissy h. Roberts

Associate Professor

London School of Hygiene & Tropical Medicine

UNITED KINGDOM

View details

Kiarash Tanha

University of Oxford

UNITED KINGDOM

View details

Tansy Edwards

Professor in Statistics and Epidemiology

Liverpool School of Tropical Medicine

UNITED KINGDOM

View details

Eric D'Ortenzio

Head

INSERM

FRANCE

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Edward Man-Lik Choi

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

A phase 1/2a clinical trial to assess safety and immunogenicity of an adenoviral-vectored capsular group B meningococcal vaccine

Using an analogue-digital hybrid clinical data management platform during a two-dose preventive Ebola virus vaccine trial in Goma, the Democratic Republic of the Congo

Delivery and Safety of a Two-Dose Preventive Ebola Virus Disease Vaccine in Pregnant and Non-Pregnant Participants during an Outbreak in the Democratic Republic of the Congo

Immunogenicity of an Extended Dose Interval for the Ad26.ZEBOV, MVA-BN-Filo Ebola Vaccine Regimen in Adults and Children in the Democratic Republic of the Congo

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

Safety and immunogenicity of an Ad26.ZEBOV booster vaccine in Human Immunodeficiency Virus positive (HIV+) adults previously vaccinated with the Ad26.ZEBOV, MVA-BN-Filo vaccine regimen against Ebola: A single-arm, open-label Phase II clinical trial in Kenya and Uganda

Safety and immunogenicity of an Ad26.ZEBOV booster dose in children previously vaccinated with the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen: an open-label, non-randomised, phase 2 trial

Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo

COVID-19 vaccines for low- and middle-income countries

In-Flight Transmission of SARS-CoV-2

Collaborators (4)

Chrissy h. Roberts

Kiarash Tanha

Tansy Edwards

Eric D'Ortenzio

Make your next move.